Cerevel Therapeutics Holdings (STU:673) Change In Receivables : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings Change In Receivables?

Cerevel Therapeutics Holdings's change in receivables for the quarter that ended in Mar. 2024 was €0.00 Mil. It means Cerevel Therapeutics Holdings's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Cerevel Therapeutics Holdings's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Cerevel Therapeutics Holdings's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Cerevel Therapeutics Holdings's Accounts Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cerevel Therapeutics Holdings's liquidation value for the three months ended in Mar. 2024 was €260.73 Mil.

Cerevel Therapeutics Holdings Change In Receivables Historical Data

The historical data trend for Cerevel Therapeutics Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Change In Receivables Chart

Cerevel Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Cerevel Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial													-	-	-	-	-

Cerevel Therapeutics Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Cerevel Therapeutics Holdings (STU:673) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cerevel Therapeutics Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Cerevel Therapeutics Holdings's accounts receivable are only considered to be worth 75% of book value:

Cerevel Therapeutics Holdings's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	778.59	-	517.857	+	0.75 * 0	+	0.5 * 0
=	260.73

Cerevel Therapeutics Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (STU:673) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CERE:USA

Address

222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141

Website

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines